J&J CFO Joseph Wolk on Q2 earnings beat: We're in a very strong position for second half of 2023 Johnson & Johnson on Thursday reported second-quarter revenue and adjusted earnings that topped Wall Street's expectations, and lifted its full-year guidance as sales from the company's medtech ...
Find the latest Revenue Earnings Per Share data for Johnson & Johnson Common Stock (JNJ) at Nasdaq.com.
Cost of Revenue$27,471,000$26,553,000$24,596,000$23,402,000 Gross Profit$61,350,000$58,606,000$55,394,000$55,338,000 Operating Expenses Research and Development$17,232,000$15,085,000$14,135,000$14,277,000 Sales, General and Admin.$22,869,000$21,512,000$20,246,000$20,118,...
We anticipate some short-term modest revenue disruption in Orthopedics of approximately $250 million in total over the next two years given the market and product line exits. But believe these actions will improve our ability to meet demand resulting in accelerated growth and enhanced profitability. ...
revenue 2021 2022 2023 2024 2025 end of interactive chart. net income bar chart with 5 bars. the chart has 1 x axis displaying categories. the chart has 1 y axis displaying values. data ranges from 14066000000 to 35153000000. net income 2021 2022 2023 2024 2025 end of interactive chart. ...
corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 36 on the 2021 Fortune 500 list of the largestUnited Statescorporations by total revenue. ...
In depth view into Johnson & Johnson (JNJ) - Consumer Health Revenue (DISCONTINUED) including historical data from 2012 to 2023, charts and stats.
Revenue/Employee643,149.891 Income Per Employee101,853.729 Receivables Turnover5.984 Total Asset Turnover0.511 JNJ Liquidity Current Ratio1.111 Quick Ratio0.863 Cash Ratio0.487 JNJ Profitability Gross Margin68.631 Operating Margin23.444 Pretax Margin18.788 ...
Cost of Revenue $27,471,000 $26,553,000 $24,596,000 $23,402,000 Gross Profit $61,350,000 $58,606,000 $55,394,000 $55,338,000 Operating Expenses Research and Development $17,232,000 $15,085,000 $14,135,000 $14,277,000 Sales, General and Admin. $22,869,000 $21,512,000...
from its closing price of $153.27 on December 20, 2023. These projections are based on forward multiples of JNJ. The significant potential for the five-year target is driven by anticipated higher revenue resulting from the Spin-off of Kenvue Inc. and promising prospects in the pharmaceutical se...